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The most appropriate level of axillary dissection for breast cancer remains unclear. The present randomised study compared the
treatment results of level-I vs level-III dissection in T1/2/3 and N0/1a/1b (1987 UICC classification) breast cancer without distant
metastasis. Between 1995 and 1997, 522 patients were enrolled, and 514 were eligible. They were stratified into breast-conserving
surgery or mastectomy, and then further stratified into level-III dissection (group-A, n¼258) or level-I dissection (group-B, n¼256).
All patients were given oral 5-fluorouracil at 200mgday
 1 and tamoxifen at 20mgday
 1, daily for 2years. Group-A resulted in a
significantly longer operation time (77.0 vs 60.5min, Po0.0001) and significantly larger blood loss (62.1 vs 48.1ml, Po0.0001) than
group-B, but in no significant differences in the frequencies of arm oedema and shoulder disturbance. Group-A resulted in a
significantly larger number of dissected nodes than group-B (18.7 vs 14.8, Po0.0001), but in no differences in the number of involved
nodes (1.54 vs 1.44). There were no significant differences in the 10-year overall and disease-free survival rates: 89.6 and 76.6% for
group-A vs 87.8 and 74.1% for group-B, respectively. In conclusion, level-III dissection resulted in a longer operation time and greater
blood loss than level-I, but did not improve the survival rate. Level-III dissection is not a recommended surgery for T1–3/N0–1b
breast cancer.
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Lymph node (LN) metastasis and tumour size are significantly
associated with the survival of patients with breast cancer.
Previously, the extent, and recently, the number of involved LN
nodes have become important prognostic factors that guide
selection of those patients who might benefit from adjuvant
treatment (Smith et al, 1977; Fisher et al, 1983). The regional LN of
breast cancer includes axillary (Ax) and internal mammary nodes.
Previously, an extended radical mastectomy, which removes
internal mammary nodes as well as Ax nodes, was one of the
standard surgeries for breast cancer; however, several randomised
controlled studies demonstrated that internal mammary dissection
was not useful to improve survival after surgery (Lacour et al,
1983; Meier et al, 1989; Veronesi et al, 1999). Accordingly, at
present, most breast surgeons dissect only Ax nodes.
However, several studies indicated that Ax dissection did not
help to improve the survival rate after surgery (Fisher et al, 1977;
Fisher et al, 1985). Furthermore, a meta-analysis using very large
samples also demonstrated that Ax dissection and radiotherapy
did not improve survival after breast cancer surgery (Early Breast
Cancer Trialists Collaborative Group, 1995), although several
researchers still reported that Ax dissection produced a signifi-
cantly higher survival rate than node-preserving surgery (Cabanes
et al, 1992). Several clinical studies demonstrated that the
incidence of Ax recurrence was very high (ranging between 18
and 35%), when clinically uninvolved Ax nodes were observed
without Ax dissection or radiotherapy (Lythgoe and Palmer, 1982;
Fisher et al, 1985; Ribeiro et al, 1993). Therefore, Ax dissection is
the standard procedure for breast cancer surgery, with the aim of
controlling local recurrence and classifying the tumour (pN) stage.
Ax dissection is classified into three levels: level-I (low-axilla),
LNs lateral to the lateral border of pectoralis minor muscle; level-II
(mid-axilla), LNs between the medial and lateral borders of
pectoralis minor muscle and the interpectoral (Rotter) LNs; and
level-III (apical axilla), apical LNs and those medial to the medial
margin of the pectoralis minor muscle.
However, Ax dissection is associated with postsurgical compli-
cations, especially arm oedema and motion disturbance of the
shoulder. Therefore, in order to reduce these complications by
avoiding unnecessary Ax dissection, a sentinel node biopsy (SNB)
or four-node biopsy has recently become popular. However, these
procedures are indicated for N0 breast cancer. Furthermore, if SNB
is positive, Ax LN should be dissected. At present, there is no
consensus what level of Ax nodes should be dissected for N1 or
node-positive breast cancer. Accordingly, the level of Ax dissection
is not only an old but also a new issue in breast cancer surgery.
The NIH consensus conference recommended level-I or level-II
dissection as standard surgery, and level-III dissection for patients
with obviously involved LNs (NIH Consensus Conference, 1991).
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sHowever, to our knowledge, there has been no randomised
controlled study comparing level-I and level-III in terms of
prognosis and complications. Therefore, at present, the most
appropriate level of dissection remains still unclear, and the
clinical significance of level-III dissection is one of the most
pressing issues in breast cancer surgery.
The present randomised controlled study was designed and
started in 1995 to compare the level-III dissection with the level-I
dissection in breast cancer patients with T1/2/3 and N0/1a/1b,
which were classified according to the UICC classification, 4th
edition (UICC, 1987), with regard to overall survival, disease-free
survival and QOL (quality of life) (especially arm oedema and
motion dysfunction of the shoulder).
PATIENTS AND METHODS
Study design
Several basic criteria had to be met before patients were included
in the study: (1) cytological proof of breast cancer, (2) curative
surgery (mastectomy or breast-conserving surgery), (3) T1–3 (no
direct invasion to the chest wall or skin), (4) N0 (no palpable Ax
nodes), N1a (movable Ax nodes not considered to contain growth)
or N1b (movable Ax nodes considered to contain growth)
according to the 1987 UICC stage classification, 4th edition (UICC,
1987), (5) performance status o3 (ECOG scale) and (6) age under
81 years.
Contraindications to patient selection included: (1) a concomi-
tant malignant disease, (2) prior surgery, chemotherapy, endocrine
therapy, radiotherapy or immunotherapy for breast cancer and (3)
an active infectious disease.
This clinical study was carried out by a single institute (Kodama
Breast Clinic, Kyoto, Japan). The end point was disease-free or
overall survival after surgery, and the trial was originally designed
to detect a difference in the 5- and 10-year survival rates between
the level-III dissection group (group-A) and the level-I dissection
group (group-B). Several studies reported that about one-third
(22–45%) of clinically node-negative breast cancers had LN
metastases (Sacre, 1983; Noguchi et al, 1993; Yang et al, 1996),
and about one third (22–43%) of patients with level-I or level-II
metastases had level-III metastases (Rosen et al, 1983: Veronesi
et al, 1987). The previous statistics demonstrated that about 30%
of patients with T1–3/N0–1 breast cancer in our clinic had nodal
involvement, and about 10% had level-III metastases. Accordingly,
if level-III metastases were left without dissection, these metastases
may have affected the prognosis of the patients, and it was
expected that there would be about 10% difference in the disease-
free survival rate and about 5% in the overall survival rate between
the level-I and level-III dissection groups. Based on this
hypothesis, when the expected difference in survival rates between
the groups was estimated as more than 5 (85 vs 90%), with 0.05 for
alpha-error and 0.05 for beta-error, during the 13 years of the
study (3 years for recruiting and an additional 10 years for follow-
up), the sample size (number of patients) needed in each group
was calculated to be 277 for each arm (totally 554) (Schoenfeld and
Richter, 1982). Based on the above, the study target was to
accumulate at least 275 patients for each arm (a total of 550).
Informed consent and the ethics committee
All patients and their families were fully informed with regard to
the study aim, treatment programme, and expected results and
clinical benefits, such as overall survival, disease-free survival and
QOL, and informed consent was then obtained. The study and
protocol were supervised and reviewed by the extramural the
Ethics and Safety Committee (Professor Syunzo Maetani, Kyoto
University and Dr Kazuhisa Ohgaki, Kyoto Police Hospital).
Patient registration and randomisation
The study was open to patients from January 1995. After informed
consent was obtained, prerandomisation was stratified with regard
to the method of surgery, breast-conserving surgery/mastectomy
and then the patients were pre-enrolled into the registration centre
by fax one day before surgery. According to Zelen’s design (Zelen,
1979), the patients were prerandomised with minimisation to
balance the prognostic factors in individual institutes, with regard
to T – primary tumour (T0/1/2/3), N – nodal involvement (N0/1a/
1b) and menopause (pre/post: if the menopausal state was
unknown, patients over 50 were classified as menopause).
On the day of the surgery, according to the fax on direction of
the randomisation from the registration centre, the patients who
received each surgery were randomly assigned to one of two
groups, group-A and group-B, and underwent an assigned level of
Ax dissection (Figure 1). After surgery, the stage of breast cancer
was classified according to the UICC (TNM) stage classification
system, 1987, 4th edition (UICC, 1987). The registration centre was
located at the Department of Medical Technology, Kyoto
University School of Medicine, and the randomisation was directed
by Professor Syunzo Maetani and his staffs.
The treatment protocol
The treatment protocol is summarised in Figure 1. The patients
were first assigned into the two arms: mastectomy and breast-
conserving surgery groups, and then each group were further
classified into two arms, group-A (level-III dissection) and group-
B (level-I dissection), respectively. From the seventh day after
surgery, all patients were orally administered 5-fluorouracil (5-FU)
at 200mgbody
 1day
 1 and tamoxifen (TAM) at 20mgbody
 1,
daily for 2 years. The patients, who underwent breast-conserving
surgery, received radiotherapy to the remnant breast at 2.0Gy 25
times (total dose of 50Gy) from the 14th day after surgery.
Examinations of haematology, serum biochemistry, serum
tumour markers and evaluation of symptomatic and performance
status were routinely performed. If recurrence appeared, the
patients were offered alternative regimens.
Evaluation of postsurgical complications
The present study was also designed to compare the frequency of
postsurgical complications, such as an arm oedema (swelling) and
Ax fluid retention, which are characteristic of breast cancer
surgery, in level-III vs level-I dissection. Arm oedema (swelling)
was evaluated according to the maximum circumference size of the
operated-side arm in comparison with the contralateral arm as
follows: (1) severe, 3cm or larger; (2) moderate, larger within
Surgery
Mastectomy
Breast-conserving
Group-A: Level-III dissection
Group-B: Level-I dissection
Group-A: Level-III dissection
+ radiotherapy to conserved breast
Group-B: Level-I dissection
+ radiotherapy to conserved breast
Figure 1 Stratification of the patients. From 1week after surgery, all
patients received oral 5-FU at 200mgday
 1 and tamoxifen at 20mgday
 1
for 2 years.
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s1–3cm; and (3) negative, same or less than 1cm larger. The
motion dysfunction of the shoulder was evaluated as follows: (1)
severe, disturbance in daily life or frozen shoulder; (2) moderate,
muscle atrophy or weakness without disturbance in daily life; and
(3) negative, no disturbance.
The lymph oedema and the arm dysfunction were evaluated by
two staffs, the doctor and the nurse, separately, who were blinded
to the extent of surgery, routinely at 3-month intervals for 2 years
after surgery.
Patient follow-up
All patients were followed by physical examination, general X-ray
examination, ultrasonography, computed tomography, routine
haematologic and biochemical examinations, and serum tumour
marker assays. The postsurgical status of all patients was surveyed
on December 2005. The median follow-up period was 9.3 years.
Statistical analysis
During the course of this 10-year study, the UICC stage
classification changed from the 4th edition to the 6th edition
(UICC, 2002). Therefore, the final results were analysed according
to the new classification. Chi-squared and Mann–Whitney U-tests
were used to compare the backgrounds of patients between each
group. The overall survival and disease-free survival were the true
end points. Survival was calculated by the Kaplan–Meier method.
A statistical comparison of the survival rates among the three
groups was made by the generalised-Wilcoxon test. Multivariate
analysis of the maximum-likelihood estimates using Cox’s
proportional-hazard model was used to obtain the conditional
risk of breast cancer-related death. All analyses were performed
using StatView software (SAS Institute Inc., Cary, NC, USA), and a
P-value less than 0.05 was considered statistically significant.
RESULTS
A total of 522 patients were registered, and eight patients were
ineligible: seven for distant metastasis to bone and one for level-II
dissection. As a result, a total of 514 patients were eligible for
analysis in the study. The comparisons among background factors
of the eligible patients are summarised in Table 1. Group-A
included 96 mastectomies and 162 breast-conserving surgeries,
and group-B included 95 mastectomies and 161 breast-conserving
surgeries. There were no significant differences in the background
factors, such as clinical stage, histology and age.
The surgical procedures and the related complications were
summarised in Table 2. The level-III dissection usually took longer
time and more blood loss for surgery than the level-I dissection:
the mean operation time was 77.0min for group-A vs 60.5min for
group-B (Po0.0001) and the mean bleeding volume was 62.1ml
for group-B vs 48.1ml for group-A (Po0.0001). There were no
significant differences in the frequencies of postsurgical arm
oedema and shoulder disturbance between group-B and group-A.
The distribution of dissected nodes was summarised in Table 3.
The mean number of dissected nodes was 18.7 for group-A vs 14.8
for group-B, and the level-III dissection resulted in significantly
larger number of dissected nodes (Po0.0001). However, there
were no differences in the number of involved nodes between
group-A (1.54) and group-B (1.44). Table 4 summarised a
distribution of involved nodes at each dissection levels in group-
A. Out of 88 patients with nodal metastases, 61 (23.6%) had
metastases only at level-I nodes. The metastases beyond the level-II
were seen in 27 patients (10.5%): level-I and -III, 14 (5.4%); level-I
and -II, 4 (1.6%); level-I, -II and -III, 4 (1.6%); level-II alone, 4
(1.6%); and level-III alone, only one patient (0.4%).
Table 1 Background of the eligible patients
Group-A
(level-III),
n¼258
Group-B
(level-I),
n¼256 Statistics
Age: mean7s.d. 50.6710.1 51.6710.6 NS
Menopause (or 450 years) 127 131 NS
Premenopause (p50 years) 131 125
ER
(+) 161 141
( )7 5 9 5
Unknown 22 20
T-factor
Preoperative evaluation
T1 113 118 NS
T2 139 130
T3 6 8
Postsurgical evaluation
Tis 12 7 NS
pT1 108 114
pT2 131 127
pT3 7 8
N-factor
Preoperative evaluation
(1987 UICC, 4th edition)
N0 (no palpable nodes) 152 149 NS
N1a (movable but not considered
no growth)
74 66
N1b (movable considered to
contain growth)
32 41
Postsurgical evaluation (2002 UICC,
6th edition)
pN0 170 179 NS
pN1 (1–3 positive nodes) 62 49
pN2 (4–9 positive nodes) 10 19
pN3 (10 or more positive nodes) 16 9
Preoperative stage (1987 UICC,
4th edition)
I 183 195 NS
II 54 60
III 21 1
Postsurgical stage (2002 UICC,
6th edition)
01 2 7 N S
I7 7 9 2
II 143 128
III 26 29
Surgery
Mastectomy 96 95 NS
Breast-conserving surgery 162 161
ER¼oestrogen receptor; NS¼no significant differences; UICC¼International
Union Against Cancer.
Table 2 Surgery and its related complications
Group-A
(level-III)
Group-B
(level-I) Statistics
Operation time (min) 77.0714.2 60.579.8 Po0.0001
Bleeding (ml) 62.1739.6 48.1729.2 Po0.0001
Number of removed LNs 18.775.5 14.874.6 Po0.0001
Postsurgical complication
Arm oedema 15 (5.8%) 14 (5.5%) NS
Shoulder disturbance 22 (8.5%) 21 (8.2%) NS
LN¼lymph node; NS, no significant differences. Values indicate mean7s.d.
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sThe recurrences were summarised in Table 5. The recurrences
were seen in 53 (20.6%) patients in group-A and 58 (22.7%)
patients in group-B. The first recurrence was seen most frequently
at LNs in both groups: 18 in group-A and 16 in group-B, and most
of them were seen at supraclavicular nodes: 15 in group-A and 15
in group-B, and at the Ax nodes no recurrence was seen in group-
A and the only one recurrence was seen in group-B. Local
recurrences were seen in 15 patients in group-A and 13 in group-B.
Distant metastases were seen in 20 patients in group-A and 28 in
group-B, and bone and lung were the major sites of the first
recurrence. There were no significant differences in the frequency
or site of the first recurrence.
The survival rates are summarised in Table 6 and Figure 2.
There were no significant differences in the overall survival and
disease-free survival between group-A and group-B (Figure 2). The
5- and 10-year overall survival rates were 93.6 and 89.6% for
group-A vs 94.5 and 87.8% for group-B, respectively (P¼0.5526).
The 5- and 10-year disease-free survival rates were 84.7 and
76.6% for group-A vs 83.1 and 74.1% for group-B, respectively
(P¼0.6137).
Multivariate analyses indicated that pT, pN and oestrogen
receptor expression were significant variables for overall survival,
Table 3 Results of the Ax dissection
Group-A
(level-III),
n¼258
Group-B
(level-I),
n¼256 Statistics
Level-I
Involved nodes 1.2973.25 1.4474.15 NS
Dissected nodes 13.7374.12 14.8174.65 P¼0.0057
Level-II
Involved nodes 0.0770.35
Dissected nodes 1.0871.39
Level-III
Involved nodes 0.1870.73
Dissected nodes 3.8971.98
Total
Involved nodes 1.5473.92 1.4474.15 NS
Dissected nodes 18.7275.47 14.8174.65 Po0.0001
Ax¼axillary; NS¼no significant difference.
Table 4 Distribution of involved nodes in level-III dissection
Involvement
Group-A
(level-III
dissection),
n¼258
Group-B
(level-I
dissection),
n¼256
Level
I(  ) 175 (67.8%) 179 (69.9%)
(+) 83 (32.2%) 77 (30.1%)
II ( ) 246 (95.3%)
(+) 12 (4.7%)
III ( ) 239 (92.6%)
(+) 19 (7.4%)
Combinations
I( )/II( )/III( ) 170 (65.9%)
I(+)/II( )/III( ) 61 (23.6%)
I(+)/II(+)/III( ) 4 (1.6%)
I(+)/II( )/III(+) 14 (5.4%)
I(+)/II(+)/III(+) 4 (1.6%)
I( )/II(+)/III( ) 4 (1.6%)
I( )/II( )/III(+) 1 (0.4%)
Table 5 Postsurgical recurrence
Group-A
(level-III),
n¼258
Group-B
(level-I),
n¼256 Statistics
Recurrence 53 (20.55%) 58 (22.65%) NS
Primary recurrent site
Local recurrence 15 (5.81) 13 (5.08%)
Contralateral breast 0 (0%) 1 (0.39%)
Nodal metastasis 18 (6.98%) 16 (6.25%)
Axillary 0 (0%) 1 (0.39%) NS
Contralateral axillary 1 (0.39%) 0 (0%)
Supraclavicular 15 (5.81%) 15 (5.86%)
Parasternal 2 (0.78%) 0 (0%)
Distant metastasis 20 (7.8%) 28 (10.9%) NS
Bone 8 (3.10%) 11 (4.30%)
Lung 7 (2.71%) 10 (3.91%)
Liver 3 (1.16%) 5 (1.95%)
Others 2 (0.78%) 2 (0.78%)
Death due to
Breast cancer 24 (9.30%) 29 (11.33%) NS
Other diseases 6 (2.33%) 6 (2.35%)
NS¼no significant difference.
Table 6 Postsurgical survival rates
Group-A
(level-III) (%)
Group-B
(level-I) (%) Statistics
I. Overall survival
5-year 93.6 94.5
10-year 89.6 87.8 NS
II. Disease-free survival
5-year 84.7 83.1
10-year 76.6 74.1 NS
NS¼no significant difference.
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Figure 2 Overall survival curves and disease-free survival curves. The
5- and 10-year overall survival rates were 93.6 and 89.6% for group-A
(n¼258) vs 94.5 and 87.8% for group-B (n¼256), respectively
(P¼0.5526). The 5- and 10-year disease-free survival rates were 84.7
and 76.6% for group-A vs 83.1 and 74.1% for group-B, respectively
(P¼0.6137).
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sand age, pT and pN were significant variables for disease-free
survival (Table 7). The level of Ax dissection was not a significant
variable for either overall survival or disease-free survival.
DISCUSSION
In the present study, LN metastases were seen in 30.1–32.2%
of the patients at level-I LNs, in 4.7% at level-II LNs and 7.4%
at level-III LNs. Of these, level-I metastases alone were seen in
23.6%, and level-II and/or level-III metastases were seen in
10.5% of the patients, suggesting that level-I dissection alone
results in an increase in the recurrence rate and a decrease in
survival rates, equivalent to about 10% (27 patients). The present
study aimed to clarify this issue, and the results indicated that
there were no differences in overall survival and disease-free
survival between the level-I and level-III dissection groups in
patients with N0 or N1a breast cancer. Furthermore, there were no
differences in arm oedema or motion disturbance of the shoulder
between level-I and level-III dissection groups. The advantage of
level-I dissection was seen in the surgical procedure, and the
operation time and blood loss were significantly shorter and
smaller than those for level-III dissection. These results were
expected, considering the complicated procedure for level-III
dissection.
The overall recurrence rates were 22.7% for level-I and 20.6% for
level-III, and there were no significant differences between them.
With respect to Ax recurrence, only one Ax recurrence was seen in
the level-I group and no Ax recurrence was seen in the level-III
group. Most LN recurrences were seen at the supraclavicular LNs,
and there were no differences in its incidence between the level-I
and level-III groups. Furthermore, there were also no differences in
local recurrence between the two groups. Accordingly, the present
results indicated that level-III dissection did not improve the local
control in comparison with level-I dissection.
Distant metastases were seen in 28 patients (10.9%) of group-B
(level-I) and in 20 patients (7.8%) of group-A (level-III), and the
initial sites of the distant metastases were seen in bone or the lungs
in most cases in both groups. There were no significant differences
between them. Therefore, level-III dissection did not contribute to
inhibiting distant metastases.
The above results suggest that level-I dissection may be
adequate for breast cancer of T1–3 with N0–1b stage. In the
present study, the patients in these categories were expected to
have a 10.5% rate (about 27 cases) of metastases in level-II and
level-III LNs. Accordingly, level-III dissection was expected to
improve survival or recurrence rates, but level-III dissection did
not improve the survival rate or recurrence rate equivalent to this
value. In addition, multivariate analyses indicated that the level of
Ax dissection was not a significant variable for overall survival and
disease-free survival, and these results also support the idea that
the level of Ax dissection has no influence on the prognosis after
breast cancer surgery.
It is unclear why there were no differences in overall survival,
disease-free survival and the recurrence rate between level-I
and level-III dissections. The present results demonstrated that
level-III dissection removed only four more LNs than
level-I dissection, and four LNs may be too small to produce a
significant difference in the patients’ outcome, and this may be one
of the reasons. However, recurrence was not seen at level-II or
level-III areas in group-B, suggesting that these LN metastases
might have spontaneously disappeared in group-B patients. These
results are compatible with previous studies on internal mammary
dissection. Metastases to internal mammary nodes were seen
in about 20% of breast cancer cases (Lacour et al, 1976), and
9.1–13.8% of patients without Ax node metastases had internal
mammary nodes metastases (Urban and Castro, 1971; Veronesi
et al, 1985). Previously, in order to remove internal mammary
nodes, a variety of extended radical mastectomy techniques were
applied in breast cancer surgery; however, several randomised
controlled studies demonstrated that internal mammary dissection
did not improve the survival after surgery and the frequency of
recurrence at the internal mammary nodes was lower than
expected (Lacour et al, 1983; Meier et al, 1989; Veronesi et al,
1999).
The reasons why involved nodes disappeared are unclear, but we
have three possible hypotheses: one is that the postsurgical
adjuvant therapies were effective at controlling the local growth of
the tumours. In the present study, the patients received an
adjuvant therapy with oral 5-FU and TAM. TAM is the gold
standard for adjuvant endocrine therapy after breast cancer
surgery (Early Breast Cancer Trialists’ Collaborative Group, 1998;
Stewart et al, 2001). However, oral 5-FU as adjuvant therapy is not
popular in the USA and Europe. In Japan, oral chemotherapy with
5-FU or its derivatives has been widely applied as a beneficial
adjuvant therapy after breast cancer surgery (Tominaga et al, 2003;
Noguchi et al, 2005; Shimane Breast Cancer Study Group, 2006),
and this study may also support the survival benefits of oral
adjuvant chemotherapy with 5-FU or its derivatives. The second
possibility is that microscopic residual tumour cells might be
eliminated by an immunosurveillance system, which may be
activated by removal of the main tumours. The third possibility is
that the nodes located at the central site of the dissected nodes may
be withdrawn due to the shut down of lymphatic circulation, even
if they are involved.
The present results indicate that level-III dissection is not
necessary for N0–1b (N0–1 by 2002 UICC) breast cancer, and
suggest that if SNB is positive, the level-I dissection is indicated.
This is a very important indication for breast-conserving surgery.
SNB is indicated for N0 breast cancers, and most of them are also
indicated for breast-conserving surgery. Since level-III LNs locate
behind the major pectoral muscle, the procedure of level-III
Table 7 Multivariate analyses using Cox’s proportional-hazard risk model
Overall survival Disease-free survival
Variable Risk ratio (95% confidence) P-value Risk ratio (95% confidence) P-value
Age 0.988 (0.960–1.017) 0.4143 0.964 (0.945–0.983) 0.0003
pT (1/2/3) 2.293 (1.353–3.884) 0.0020 2.254 (1.563–3.250) o0.0001
pN (0/1/2/3) 2.073 (1.568–2.740 o0.0001 2.191 (1.804–2.662) o0.0001
ER (0/1) 0.395 (0.222–0.701) 0.0015 0.848 (0.571–1.259) 0.4136
Level of dissection (1/3) 0.964 (0.721–1.290) 0.8067 0.995 (0.8151–1.215) 0.9634
No. of dissected nodes 0.987 (0.938–1.039) 0.6156 0.969 (0.934–1.006) 0.1032
ER¼oestrogen receptor.
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sdissection is not so easy for breast-conserving surgery with a small
Ax incision for SNB and sometimes an additional large incision,
which may result in a cosmetic problem, if necessary.
As discussed above, the present study indicated that
level-III dissection is not necessary for T1–3/N0–1b breast
cancer.
CONCLUSION
The present study indicated that level-III dissection did not
improve the survival rate, but did result in a longer operation time
and a greater blood loss than level-I dissection. Level-III dissection
is not a recommended surgery for T1–3/N0–1b breast cancer.
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